Anaveon AG is a Swiss clinical-stage biopharmaceutical company dedicated to developing novel, life-changing immuno-oncology therapies. Leveraging its expertise in immunology and antibody engineering, Anaveon aims to create powerful therapeutics that selectively activate anti-tumor immune responses. Their lead programs, including ANV419 (a selective IL-2R agonist) and ANV600 (an IL-12 immunocytokine), are designed to overcome the limitations of existing cytokine therapies by maximizing efficacy and minimizing toxicity. The company focuses on a deep understanding of cytokine biology to create next-generation treatments for cancer patients.
The headquarters serves as the primary center for Anaveon's research and development activities, clinical trial management, corporate administration, and strategic operations.
Located within a modern life sciences park, the facility likely offers access to state-of-the-art laboratory spaces and fosters a collaborative research environment typical of biotech clusters.
Anaveon promotes a science-driven, innovative, and collaborative work culture. The environment encourages intellectual curiosity, teamwork, and a strong commitment to developing impactful therapies for patients.
Its location in Schlieren provides strategic advantages, including access to a skilled talent pool, proximity to academic research institutions, and a supportive ecosystem for biotechnology innovation and growth.
While Anaveon AG is headquartered in Switzerland, its operations, particularly clinical trials and potential scientific collaborations, have a global reach. The company engages with international partners and clinical sites to advance its immuno-oncology pipeline for patients worldwide. Its drug development programs aim to address global unmet medical needs in oncology.
Wagistrasse 27
Schlieren
Zurich
Switzerland
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ANAVEON AG' leadership includes:
ANAVEON AG has been backed by several prominent investors over the years, including:
Anaveon AG has strengthened its leadership team over the past 12-18 months with strategic appointments in finance and legal affairs, enhancing its capabilities as it advances its clinical programs. No major executive departures have been publicly announced during this period.
Discover the tools ANAVEON AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Anaveon AG likely uses standard professional email address formats. Common patterns include [first_initial][last]@anaveon.com or [first].[last]@anaveon.com. For example, Jane Doe might be jdoe@anaveon.com or jane.doe@anaveon.com.
[first_initial][last]@anaveon.com
Format
jdoe@anaveon.com
Example
75%
Success rate
Business Wire • March 6, 2024
Anaveon AG, a clinical-stage immuno-oncology company, today announced the appointment of Priya Gurg, J.D., as General Counsel. Ms. Gurg brings over 15 years of extensive legal and strategic experience in the biopharmaceutical industry to Anaveon....more
Business Wire • January 4, 2024
Anaveon AG announced that the first patient has been dosed in its Phase I/II clinical trial evaluating ANV600 for the treatment of patients with solid tumors. ANV600 is a first-in-class, IL-12-based immunocytokine designed to selectively deliver IL-12 to the tumor microenvironment, thereby maximizing its anti-tumor activity while minimizing systemic toxicity....more
Business Wire • May 16, 2023
Anaveon AG, a clinical-stage immuno-oncology company, today announced the appointment of Régis Lerebours, PharmD, MBA, as Chief Financial Officer (CFO). Mr. Lerebours brings over 20 years of international finance and leadership experience in the pharmaceutical and biotech industries....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ANAVEON AG, are just a search away.